A practical framework categorizes TKIs into three classes to guide adjuvant use. Class 1 (e.g., osimertinib, alectinib) has high efficacy and low toxicity, making extrapolation easy. Class 2 (e.g., BRAF/MET inhibitors) has moderate efficacy and higher toxicity, requiring trials. Class 3 (e.g., KRAS inhibitors) has lower activity and needs trials.

The next therapeutic frontier for RAS-mutated cancers involves combining multi-selective RAS inhibitors (e.g., daraxonrasib) with mutation-specific inhibitors (e.g., zoldon-rasib). This dual-pronged strategy aims to achieve deeper and more durable pathway inhibition by attacking the target through different mechanisms simultaneously.

In ROS1-positive NSCLC, starting with older TKIs before newer agents like Repotrectinib dramatically worsens outcomes. Median overall survival has not been reached after 5 years for TKI-naive patients but drops to just 25 months for those pre-treated with another TKI. This starkly quantifies the critical importance of using the most effective treatment first.

While both Talatrectinib and Repotrectinib show impressive efficacy in ROS1-positive NSCLC, the choice between them can hinge on their side effect profiles. Talatrectinib demonstrates lower rates of TRK-related adverse events like dizziness, offering a key advantage in clinical practice.

Clinicians are becoming more comfortable extrapolating positive adjuvant trial data from established targets like EGFR and ALK to other mutations like ROS1, even without specific Phase 3 evidence. This practice is particularly considered for patients in high-risk settings like locally advanced disease.

A common clinical pitfall is treating RAS/BRAF wild-type anal cancer with anti-EGFR antibodies, extrapolating from rectal adenocarcinoma protocols. Retrospective data shows this approach has only modest efficacy (4-5 month PFS) and is not a recommended strategy, highlighting a key difference between the two diseases.

For patients with actionable mutations like EGFR or ALK, targeted therapy is the priority, regardless of PD-L1 score. Starting immunotherapy first in these patients can significantly increase the risk of developing severe pneumonitis (ILD) when they later switch to targeted therapy like osimertinib.

For critical driver mutations like ROS1 and ALK fusions, relying solely on DNA-based Next-Generation Sequencing (NGS) is insufficient. A study showed that a significant portion of these fusions are only detectable via RNA sequencing. Clinicians must verify that RNA analysis was included in NGS reports to avoid missing effective targeted therapies for one in five potential patients.

While pan-RAS inhibitors like daraxoracib show broad efficacy irrespective of mutation, allele-specific agents may have fewer side effects and more predictable resistance patterns. This creates a clinical trade-off between immediate applicability and a more tailored, potentially better-tolerated long-term strategy.